Company ProfilePremium

Daesung Microbiological Labs. Co., Ltd.

Company Profile Analysis

Ticker: 036480.KQ주

ESOMAR 23 Corporate BadgeISO Certifications Badge
Daesung Microbiological Labs. Co., Ltd. - Company showcase

Year Founded & Workforce

1966

138 Employees

Daesung Microbiological Labs. Co., Ltd. logo

Daesung Microbiological Labs. Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Daesung Microbiological Labs. Co., Ltd. Overview

Daesung Microbiological Labs is one of Korea's oldest veterinary pharmaceutical manufacturers. It makes about 150 products for cattle, pigs, poultry, bees and companion animals at a single integrated site in Uiwang, Gyeonggi Province. The portfolio covers inactivated and live vaccines, antibiotics, antibacterials, anthelmintics, nutritional and probiotic products, anti-inflammatories, immunostimulants and disinfectants. No single product exceeds roughly 5–10% of sales. The business is predominantly domestic (≈74–80% of revenue). It sells through about 200 dealers, NongHyup channels and Public Procurement Service (PPS) contracts for government vaccination programmes, notably foot-and-mouth disease (FMD) vaccines. Exports go to six countries led by Pakistan, Vietnam and Russia. After four years of stagnant revenue (~KRW 24–26bn) and losses in 2022–2024, it returned to a thin profit in 2025. In March 2026, AI and in-silico consultancy InSilico acquired control. InSilico plans to use DX/AX tools, a bioreactor scale-up and partner-led global distribution to roughly double revenue to KRW 50bn within three years.


What the company does

The company develops, manufactures and sells animal medicines (동물용의약품). Its own disclosures describe about 150 products, grouped as follows:

Preventive vaccines (예방백신): inactivated (killed) and live attenuated vaccines for swine, poultry, cattle and dogs, including FMD vaccines supplied under PPS contracts.

Antibiotics (항생제) and antibacterials (항균제): - Anthelmintics / dewormers (구충제).

Nutritional supplements (영양제): - Antipyretic-analgesic-anti-inflammatory agents (해열진통소염제).

Live-bacteria / enzyme preparations (생균효소제, probiotics): - Immunostimulants (면역증강제).

Disinfectants (소독제): (Source: company description as reported by eToday, 2026-02-15, which draws on the company's periodic report.)

A distinctive feature disclosed by the company is a highly diversified revenue base: the largest individual products each account for only about 5–10% of sales.

Business and revenue model

The company is a product manufacturer. All revenue comes from product sales; it has no subscription, licensing or service revenue. It reports no material royalty income, and the income statement shows no royalty line in FY2025 (ValueLine). Revenue reaches customers through three channels:

  1. Domestic dealer network. Direct sales through about 200 animal-medicine dealers (대리점) serving livestock farms. Companion-animal products such as the VLP canine influenza vaccine go through veterinary wholesalers to animal hospitals.

  2. Government procurement. Supply contracts won through the Public Procurement Service (조달청), under which preventive vaccines are delivered to government bodies nationwide. FMD vaccine "multiple-supplier contracts" have recurred annually since at least 2023. The press also cites supply to NongHyup (농협) as a domestic channel.

  3. Exports. Sales to six countries centred on Pakistan, Vietnam and Russia. The company added channels in Cambodia in 2025 and markets to Uzbekistan, South America, the Middle East and Mongolia.

(Sources: eToday 2026-02-02 and 2026-02-15; Dealsite 2026-03-27.)

Value-chain position

Daesung is a vertically integrated formulator-manufacturer. It carries out antigen production (cell culture, virus inoculation and propagation), harvesting, purification and concentration, inactivation or freeze-drying, filling, sealing and labelling in-house at the Uiwang plant. Its raw materials include cell-culture media, adjuvants, active pharmaceutical ingredients and packaging; raw materials cost ~KRW 9bn a year (ValueLine, FY2025 TTM). Some products rest on technology in-licensed from public research bodies: the VLP canine influenza vaccine and the G2b PED live vaccine both use technology from the Animal and Plant Quarantine Agency (APQA), and Konkuk University transferred live-vaccine technology in 2015.

Customer types and end markets

End marketCustomer typeProductsChannel
SwineCommercial pig farmsPED vaccines (G2b live and inactivated), bacterial respiratory disease vaccines, antibiotics, FMD vaccinesDealers, PPS, export
CattleBeef and dairy farmsFMD vaccines; anthrax/blackleg live mixed vaccine (historic PPS item)PPS, dealers
PoultryBroiler and layer farmsPoultry vaccines, antibacterials, nutritional productsDealers, export
Apiculture (bees)BeekeepersBee medicines (disclosed as part of the ~150 products)Dealers
Companion animalsVeterinary hospitalsDaesung VLP Flu Dogivac (canine influenza)Veterinary distributors
GovernmentMunicipal and provincial animal-disease agenciesFMD and other national-programme vaccinesPPS multiple-supplier contracts

Independent characterisation

On the evidence, Daesung is a sub-scale, domestically anchored, broad-line livestock pharmaceutical manufacturer with modern GMP biologics capacity. Its KVGMP vaccine plant was completed in 2021, and the Uiwang plant holds a Eurasian GMP certificate. Revenue has been flat for a decade: KRW 30.8bn in FY2016 versus KRW 26.0bn in FY2025. Gross margins compressed from ~33% (FY2016–2020) to 17–25% (FY2021–2025) as depreciation on the new plant and higher input costs absorbed the gross profit pool. Its competitive identity rests on breadth, a long-standing dealer franchise, eligibility for PPS vaccine programmes, and a few technically differentiated vaccines (VLP and G2b PED). Its main structural weaknesses are low export penetration relative to peers, thin margins, and dependence on volatile government disease-control demand. The 2026 change of control turns the investment case into an execution story about export scale-up and manufacturing productivity under a technology-oriented owner.

Strategy

Stated strategic themes (paraphrased)

The company does not hold investor days. Strategy is drawn from the periodic report summary (via FnGuide/eToday) and the new owner's statements.

  1. Product development matched to disease trends. The company says it develops products targeted at currently prevalent diseases and pathogen variants and launches new products steadily (eToday, 2026-02-15).

  2. New facility investment to enter advanced markets. The KVGMP investment is framed as the base for regulated export markets (eToday, 2026-02-02).

  3. Overseas expansion. Trade fairs, exhibitions and farm visits in Vietnam, Cambodia, South America, the Middle East and Uzbekistan (eToday).

InSilico-era strategy (from March 2026)

HorizonInitiativeDetailSource
Short termExport scale-up via partnersShift from country-by-country direct sales to inclusion in global distributors' portfolios. Talks with a feed company covering SE Asia, the Middle East, Africa and the Americas. Management will accept lower margins for faster market entry.Dealsite 2026-03-27
Short termSales organisation reorganisationInternal restructuring weighted to overseas sales (not finalised)Dealsite
Medium termDX/AX manufacturing efficiencyApply InSilico's digital and AI tools to optimise culture conditions, detect process anomalies early and reduce batch variability. The plant is currently accumulating process data.Dealsite 2026-03-27
Medium termSuspension culture and bioreactorsConvert adherent culture to suspension; introduce bioreactors by ~2028 for large-scale productionDealsite
Long termNew product developmentUse AI-based drug design and in-licensed immunology IP for new animal drugsDealsite 2026-03-10
Long termGlobal positioningAspiration to make the company a global leader within five yearsDealsite 2026-03-27

Financial targets (owner-stated, not formal guidance)

TargetValueHorizonSource
RevenueKRW 50bn (about 1.9x FY2025)Within 3 years (by ~2029)Dealsite 2026-03-10/27; BioTimes
Operating margin10%Within 3 yearsSame
Share price2xWithin 3 yearsDealsite 2026-03-10
Export revenueFrom ~KRW 5bn to KRW 20bn+Not specifiedDealsite 2026-03-27

ESG or sustainability commitments, cost programmes with quantified targets: none disclosed.

Products & Services

The company does not publish a full catalogue in the sources reviewed. The table below lists every product or product family that could be verified, organised by the single segment and its therapeutic families. Pricing is not disclosed for any product.

Manufacturing formats (Dealsite plant visit, 24 March 2026):

Inactivated vaccines: are made in Building M: pathogen inactivation, adjuvant blending, then fill and seal.

Live vaccines: are made in Building E: lyophilisation, then filling into heat-sterilised vials.

  • The site also has injectables, chemicals and animal-testing buildings.

  • Inactivated and live lines are fully separated, with species-segregated antigen suites.

Note: in 2019 the shares spiked on retail interest in canine dewormers (fenbendazole) as a purported human cancer therapy (eToday headline). This was a market-sentiment episode, not a product launch.

Product Portfolio

Product / familyDescription & key capabilitiesTarget customerLaunch / latest yearNotes / source

Daesung VLP Flu Dogivac (대성 VLP 플루 도기백주, "브이엘피플루")

Canine influenza (H3N2) vaccine using a recombinant virus-like particle (VLP) antigen with no viral genetic material. Cell-culture produced, which lowers egg-allergy risk. Licensed for subcutaneous injection; press describes it as Korea's only subcutaneous canine influenza vaccine. National lot-release approved by APQA.

Veterinary hospitals (dogs and cats)

c. 2021 (launch under CEO Cho Hang-won)

Korea's first VLP animal vaccine. Technology transferred from APQA. Sold only to animal hospitals via Woorienpharm, BK Pharm, Busan Veterinary Pharm, VS Pharm, VD House, Kyungsu Pharm and, later, Seoul Veterinary Pharm (DailyVet)

Daesung PED-Q Live Pigvac (대성 PED-Q Live 피그백주)

G2b-genotype porcine epidemic diarrhoea live vaccine. Korea's first usable by intramuscular injection or orally. Built on an APQA live-attenuated G2b strain. A 10x overdose safety trial in pregnant sows showed no adverse effects.

Pig farms (sows, pre-farrowing)

2022

Designated an MAFRA "Excellent R&D Innovative Product" (c. July 2023). Sold through dealers, the national e-procurement mall (나라장터) and the Innovation Market (DailyVet)

Daesung PED-Q Pigvac (대성 PED-Q 피그백주)

G2b PED inactivated vaccine, recommended in live-live-killed or live-live-killed-killed priming sequences with PED-Q Live

Pig farms

Pre-2022 (exact year not disclosed)

DailyVet

Porcine bacterial respiratory disease vaccines

Vaccines against bacterial respiratory pathogens in swine; efficacy data presented at FAVA 2024

Pig farms

—

DailyVet (FAVA 2024 coverage)

FMD vaccines (구제역백신), 2 types

Supplied to the PPS under annual multiple-supplier contracts: 95,500 vials (2023), 100,000 vials (2024–25) and 115,000 vials (2025–26). The 2025 disclosure states they are self-produced.

Government animal-disease agencies

Recurring annually

DART via Digital Today / Edaily

Anthrax and blackleg live mixed vaccine (탄저·기종저 생균혼합백신)

Cattle bacterial vaccine; part of an 18-vaccine PPS award

Cattle farms / government

Historic (c. 2011 contract)

eToday

Other PPS vaccine families

9 vaccine types (1,048,000 vials) supplied in the 2020 PPS contract

Government

2020

eToday

Antibiotics (항생제)

Livestock antibiotics (specific molecules not disclosed)

Farms via dealers

Ongoing

eToday 2026-02-15

Antibacterials (항균제)

Synthetic antibacterials

Farms

Ongoing

eToday

Anthelmintics (구충제)

Livestock dewormers

Farms

Ongoing

eToday

Nutritional supplements (영양제)

Vitamins and minerals for livestock

Farms

Ongoing

eToday

Antipyretic-analgesic-anti-inflammatories (해열진통소염제)

Supportive therapeutics

Farms / veterinarians

Ongoing

eToday

Live-bacteria / enzyme products (생균효소제)

Probiotic and enzyme feed-administered products

Farms

Ongoing

eToday

Immunostimulants (면역증강제)

Immune-enhancing products

Farms

Ongoing

eToday

Disinfectants (소독제)

Farm biosecurity disinfectants; demand rises during ASF, FMD and HPAI outbreaks

Farms / government

Ongoing

eToday

Bee medicines

Apiculture medicines produced at Uiwang alongside cattle, pig and poultry products

Beekeepers

Ongoing

Dealsite 2026-03-27

“—” = not publicly disclosed.

Financial Narrative

All figures are from separate (non-consolidated) IFRS statements filed with DART, as aggregated by ETF Shopping, Butler and ValueLine. Units are KRW 100M unless stated.

Income statement

Sources: revenue, cost of sales, gross profit, operating income and EPS from DART via ETF Shopping and Butler. FY2025 SG&A, EBITDA, interest, pre-tax and tax from ValueLine (FY2025 annualised column). Net income from Butler. Diluted EPS is not separately disclosed in sources reviewed; no convertible or warrant instruments were identified.

Revenue CAGR. FY2021–FY2025: +2.0% p.a. (KRW 240 → 260 x100M). FY2016–FY2025: -1.9% p.a. (KRW 308 → 260 x100M). Both computed.

Quarterly trajectory (chartable):

Source: DART periodic reports via ETF Shopping (filed 2024-05-14 through 2026-08-14).

Commentary — income statement.

FY2021–FY2022: margin compression after the KVGMP investment: Revenue was stable at KRW 24–26bn, but gross margin collapsed from the ~33% achieved in FY2016–FY2020 to 23.9% in FY2021 and 18.8% in FY2022. The timing matches the 2021 commissioning of the KVGMP vaccine facility. Depreciation stepped up, and machinery on the balance sheet rose sharply again in FY2024 (KRW 87.9 → 118.1 x100M). Fixed overhead was spread over a revenue base that did not grow. FY2022 net income of KRW 1.7bn against an operating loss implies non-operating gains; their nature is not disclosed in the sources reviewed.

FY2023–FY2024: the trough: Revenue fell 6.9% in FY2024 to KRW 23.8bn. Management attributes this to weak exports in 2024 (eToday, 2026-02-15). The operating loss deepened to KRW -1.6bn and the net loss to KRW -1.8bn, the worst result of the decade. Q2 and Q3 FY2024 alone lost KRW 1.9bn at the operating line.

FY2025: inflection: Revenue grew 9.2% to KRW 26.0bn and gross margin recovered to 24.8%, so operating profit turned positive at KRW 0.71bn. Sujuradar attributes the profit recovery mainly to better profitability on existing products rather than to new launches. The company points to new export channels such as Cambodia (eToday). Growth was concentrated in Q2–Q3 FY2025 (+19.3% and +23.5% YoY). Net income was helped by a KRW 0.26bn tax benefit, because pre-tax income was only KRW 0.33bn after ~KRW 0.6bn of interest expense.

FY2026 year to date: relapse: H1 FY2026 revenue fell to KRW 11.1bn (-6.7% YoY), and both Q1 and Q2 posted operating losses of KRW 0.5bn each. On a trailing-twelve-month basis to June 2026, revenue is KRW 25.19bn, operating income KRW -0.66bn, EBITDA KRW 2.66bn and net income KRW 0.35bn (ValueLine TTM). The relapse coincides with the ownership transition and with weak drawdown on the FMD contract.

Balance sheet

Source: ValueLine balance sheet (DART separate statements). Net debt and working capital are analyst-computed. At Q1 FY2026: total assets KRW 573.4, borrowings KRW 195.4 (14.8 ST + 45.6 current LT + 135.0 LT) and equity KRW 349.2 x100M.

Commentary — balance sheet.

Asset-heavy, PP&E-dominated balance sheet: PP&E of KRW 29.6bn is 51% of total assets. It comprises buildings of KRW 15.0bn, machinery of KRW 10.7bn and land at a historic KRW 3.0bn book value. The company holds no goodwill, and intangibles are minimal and falling. Capitalised development costs shrank from KRW 0.51bn (FY2022) to KRW 0.07bn (FY2025).

Leverage is moderate on equity but heavy relative to earnings. Borrowings of ~KRW 19.6bn equal 55% of equity but about six times FY2025 EBITDA on a gross basis (3.1x net). In FY2025, KRW 4.6bn of long-term debt moved to current, creating a 2026 refinancing requirement. This is the largest near-term balance-sheet monitorable. The cash-flow data show the company refinanced roughly KRW 15.5bn of long-term debt in mid-2024, which explains the FY2024 swing from current to long-term.

Liquidity buffer: Cash plus short-term deposits of KRW 9.4bn (FY2025) cover the current portion of debt about twice over. The buffer has shrunk from KRW 12.9bn at FY2022.

Working-capital intensity is extreme: inventories are ~41% of revenue.

Cash flow

Sources: FY2025 OCF and capex from ValueLine cash-flow data (DART). Dividends paid are analyst-derived as the prior-year DPS times ~3.8M shares, consistent with the KRW 2.8 x100M dividend outflow ValueLine shows. ETF Shopping (DART) records no buybacks. The data provider computes FY2025 "free cash flow" at KRW 3.2 x100M using a broader outflow definition; the analyst figure above uses PP&E capex only. On a TTM basis to June 2026: OCF KRW 9.7 and PP&E capex KRW 3.5 x100M.

Commentary — cash flow. FY2025 OCF of KRW 1.41bn was more than twice net income because ~KRW 2.5bn of non-cash D&A was added back. About KRW 2.0bn of working-capital build partly offset this, mainly a KRW 1.4bn rise in receivables, consistent with H2 FY2025 PPS deliveries. Capex is running at maintenance level (KRW 0.35bn a year) despite the stated plan to convert from adherent to suspension culture and install bioreactors. That programme is not yet visible in cash flows, and it will need either a capex step-up or a contribution from the parent. Dividends (~KRW 0.29bn a year) have been sustained through loss years, which suggests a policy of a stable payout regardless of earnings.

Ratios

All ratios are analyst-computed from the tables above. The 22% tax rate in ROIC is an analyst assumption approximating the Korean statutory rate. ETF Shopping reports FY2025 ROE of 1.7% and ROA of 1.0%, consistent with these figures.

Commentary — ratios. Returns are well below any reasonable cost of capital: ROIC peaked at about 1% in the best recent year. Interest coverage of 1.2x in FY2025 leaves almost no cushion, and in H1 FY2026 operating income again fell short of interest expense. The cash conversion cycle of ~230–250 days is structural for a broad-line vaccine maker. Biologics require long batch lead times, release testing and seasonal stock-building for PPS programmes, so roughly KRW 10.5bn of inventory sits against KRW 19.6bn of annual cost of sales. Work-in-process rose from KRW 4.8bn (FY2024) to KRW 6.6bn (Q1 FY2026), which may be stock-building ahead of FMD and export demand that did not fully materialise. Productivity gains from DX/AX would show up first in DIO and gross margin; these are the most direct tests of the new owner's thesis.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment (KRW) and Segment Margins & Growth (%)

MetricFY2023FY2024FY2025

Veterinary pharmaceuticals – Revenue (KRW 100M)

256238260

Veterinary pharmaceuticals – Operating income (KRW 100M)

-7-167

Veterinary pharmaceuticals – Operating margin (%)

-2.7-6.52.7

Veterinary pharmaceuticals – Revenue growth YoY (%)

0.2-6.99.2

Veterinary pharmaceuticals – Share of total revenue (%)

100100100

Product Families

Product family (Q1 FY2026)Value (KRW 100M)Share of product revenue (%)

"Other products" (기타 제품군; the largest category disclosed)

33.666.1

Total product revenue, Q1 FY2026

50.82100

Income Statement (KRW) and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW 100M)

240255256238260

Cost of sales (KRW 100M)

183207207198196

Gross profit (KRW 100M)

5748484164

SG&A (KRW 100M)

————57.2

Operating income (KRW 100M)

3-3-7-167

EBITDA (KRW 100M)

————32.6

Interest expense (KRW 100M)

————6.0

Pre-tax income (KRW 100M)

————3.3

Income tax (KRW 100M; negative = benefit)

————-2.6

Net income (KRW 100M)

917-7-186

EPS basic (KRW)

227448-179-466157

Dividend per share (KRW)

7575757575

Gross margin (%)

23.918.819.017.024.8

Operating margin (%)

1.4-1.3-2.7-6.52.7

EBITDA margin (%)

————12.5

Net margin (%)

3.86.7-2.7-7.42.3

Income Statement (KRW)

MetricQ1FY2024Q2FY2024Q3FY2024Q4FY2024Q1FY2025Q2FY2025Q3FY2025Q4FY2025Q1FY2026Q2FY2026

Revenue (KRW 100M)

56565868526772695160

Operating income (KRW 100M)

-3-10-97-376-3-5-5

Balance Sheet (KRW) and Per-Share Data

MetricFY2022FY2023FY2024FY2025

Total assets (KRW 100M)

651.0642.9583.7579.7

Current assets (KRW 100M)

286.9287.1236.4252.3

Cash & cash equivalents (KRW 100M)

38.543.636.334.4

Short-term financial instruments (KRW 100M)

90.073.654.259.4

Trade receivables (KRW 100M)

30.441.337.750.2

Inventories (KRW 100M)

116.4124.9104.8105.5

Property, plant & equipment (KRW 100M)

331.3319.3314.0296.0

Goodwill (KRW 100M)

0000

Intangible assets (KRW 100M)

8.76.85.44.2

Current liabilities (KRW 100M)

106.1103.945.385.3

Short-term borrowings (KRW 100M)

20.053.110.015.0

Current portion of long-term borrowings (KRW 100M)

43.521.27.546.2

Long-term borrowings (KRW 100M)

155.0163.7181.2135.0

Total borrowings (KRW 100M)

218.5238.0198.7196.2

Net debt (borrowings less cash and ST financial instruments; KRW 100M)

90.0120.8108.2102.4

Total liabilities (KRW 100M)

262.7269.4232.3225.5

Shareholders' equity (KRW 100M)

388.3373.4351.4354.2

Working capital (KRW 100M)

180.8183.2191.1167.0

Book value per share (KRW)

10,2209,8299,2509,321

Cash Flow (KRW)

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW 100M)

————14.1

Capital expenditure, PP&E (KRW 100M)

————3.5

Free cash flow, OCF less PP&E capex (KRW 100M)

————10.6

Dividends paid (KRW 100M)

3.22.92.92.92.9

Share buybacks (KRW 100M)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025

ROE on year-end equity (%)

4.4-1.9-5.11.7

ROA on year-end assets (%)

2.6-1.1-3.11.0

ROIC, NOPAT at 22% tax / (equity + net debt) (%)

-0.5-1.1-2.71.2

Current ratio (x)

2.702.765.222.96

Debt-to-equity (x)

0.560.640.570.55

Net debt / EBITDA (x)

———3.1

Interest coverage, operating income / interest expense (x)

———1.2

Asset turnover, revenue / year-end assets (x)

0.390.400.410.45

Days sales outstanding (days)

44595871

Days inventory outstanding (days)

205220193197

Days payables outstanding (days)

17272421

Cash conversion cycle (days)

232252227246

Region (KRW 100M) Overview

Region (KRW 100M)9M FY2025Share (%)

Domestic (Korea)

14174

Export

5026

Total

191100

Region (KRW 100M) Overview (FY2025)

Region (KRW 100M)FY2025

Export (approximate, per CEO)

50

Domestic (derived: total less export)

210

Valuation Multiples (KRW) and Valuation Multiples (x)

MetricFY2022FY2023FY2024FY2025

Year-end share price (KRW)

10,30010,9509,0907,300

Year-end market capitalisation (KRW 100M)

391.4416.1345.4277.4

Year-end P/B (x)

1.011.110.980.78

Share Price & Returns

Reference pointPrice (KRW)DateSource

Intraday high during the FMD emergency

~17,130

2023-05-16

eToday

ASF spike (intraday)

8,810

2026-02-02

eToday

Limit-up on control-deal announcement

8,120

2026-03-10

JoongAng Economy News

Deal price paid by InSilico

11,000

2026-03-09

DART

Parent's market purchases (average, final tranche)

6,606

June 2026

Greened

Latest close

5,750

2026-10-20

ETF Shopping

52-week high / low

9,880 / 5,590

to 2026-10-20

ETF Shopping

Valuation Multiples

MultipleDaesungChoong Ang VaccineEagle VetWoogene B&GKomipharm

P/E on FY2025 EPS (x)

36.610.87.1

Negative

Negative

P/E on TTM to Jun-2026 (x)

62.3————

P/B (x)

0.610.800.710.5810.22

EV/EBITDA FY2025 (x)

9.8————

EV/EBITDA TTM Jun-2026 (x)

12.1————

EV/Sales FY2025 (x)

1.23————

Dividend yield (%)

1.302.152.6100

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024FY2025

Dividend per share (KRW)

7575757575

Payout ratio (%)

3317——48

Debt Maturity Profile

Maturity bucket (KRW 100M)FY2025

Short-term borrowings (≤1 year)

15.0

Current portion of long-term borrowings (≤1 year)

46.2

Long-term borrowings (>1 year)

135.0

Total borrowings

196.2

Analyst Conclusions

Guidance and expectations

Formal guidance: none issued.

Owner targets: revenue of KRW 50bn and a 10% operating margin within three years; share price to double; exports above KRW 20bn (Dealsite, March 2026).

Consensus: none (no coverage).

Run-rate reality check: H1 FY2026 revenue was KRW 11.1bn (-6.7% YoY) with a KRW 1.0bn operating loss. TTM revenue is KRW 25.2bn and TTM operating income KRW -0.66bn (ValueLine). Meeting the 3-year target from here implies roughly 25–30% revenue CAGR over FY2026–FY2029.

Bull case

  1. Export inflection via partner distribution. If the feed-company partnership is signed and products are registered, management's arithmetic implies a step-up. Moving exports from ~KRW 5bn to KRW 20bn would take revenue above KRW 40bn. Incremental volume through a plant with spare capacity would carry high incremental margins, given the fixed-cost structure (FY2025 gross margin rose 7.8pp on 9.2% revenue growth).

  2. Asset-backed downside. At 0.61x book (equity KRW 35.4bn vs market cap KRW 21.9bn), with a KVGMP plant, land carried at historic cost, a stable dividend and a parent that paid KRW 11,000/share, there is a valuation floor and a credible incentive for the parent to support the share price.

  3. Disease-cycle optionality. ASF (5th national case in Feb 2026), PED (recurring in 2026) and FMD (an emergency SAT1 procurement by a peer in July 2026) keep vaccine and disinfectant demand structurally elevated. Daesung has PPS eligibility and differentiated PED and VLP products positioned to capture spikes, as the 2023 and 2026 share-price reactions show.

Bear case

  1. Earnings relapse and weak debt cover. Two consecutive quarterly operating losses in FY2026 and TTM operating income below interest expense (~KRW 0.6bn a year) show the FY2025 recovery was not durable. A KRW 4.6bn current debt maturity adds refinancing pressure.

  2. Government-demand dependence. Only 41% of the 2025–26 FMD ceiling was executed, and no 2026–27 award had been disclosed by 20 October 2026. The largest domestic revenue line is therefore uncertain, and peers compete for the same contracts.

  3. Governance and execution uncertainty. The new owner is an IT/AI consultancy with no veterinary-manufacturing record. Its acquisition financing is undisclosed, the merger option creates minority-dilution risk, and the stated targets are aggressive relative to a decade of flat revenue.

Catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorableWhat to watch
~Mid-Nov 2026Q3 FY2026 reportReturn to operating profit; export revenue; inventory and WIP
Q4 20262026–27 PPS FMD vaccine contractAward size vs KRW 3.3–4.0bn history; drawdown visibility
H2 2026 – 2027Global feed-company distribution partnershipSigning, territories, product registrations
Nov 2026KAHPA pavilion at EuroTier 2026 (Germany)Any Daesung participation or EU-adjacent registrations
2026–2027Refinancing of ~KRW 4.6bn of current long-term debtTerms; any parent guarantee or funding
2026–2028Suspension-culture conversion and bioreactor capexCapex disclosures; gross-margin trend; DIO
Feb–Mar 2027FY2026 dividend decision and AGMWhether KRW 75 DPS is maintained; board changes
OngoingASF / FMD / HPAI / PED outbreaksEmergency procurement; disinfectant and vaccine demand
OngoingParent actions (further buying, merger, related-party contracts)DART disclosures by InSilico

Analyst verdict

Daesung Microbiological Labs is a 60-year-old Korean veterinary-medicine manufacturer at an inflection point it has not yet earned. The franchise is real: about 150 products, a dealer network of roughly 200, recurring government vaccine eligibility, a KVGMP biologics plant with Eurasian GMP, and two technically differentiated vaccines (VLP canine flu and G2b PED live). The financial record does not yet support the strategic narrative. Revenue in FY2025 (KRW 26.0bn) remained below FY2016. FY2025 was the only profitable year at the operating line since FY2021, and the operating margin was just 2.7%. The first half of FY2026 slipped back into losses as government FMD drawdowns fell to 41% of contract ceiling.

The March 2026 sale of the founding family's 38.6% stake to InSilico, at a 74% premium, reframes the case. The new owner has set aggressive goals (KRW 50bn revenue, 10% OPM and a doubled share price within three years) and a coherent playbook: partner-led exports, data-driven process optimisation, and a bioreactor scale-up. The plan's logic is sound because the plant has operating leverage and exports are under-penetrated relative to peers such as Choong Ang Vaccine. Execution capability in animal-health manufacturing is unproven, the financing and related-party arrangements are opaque, and interest coverage near 1x leaves little room for delay.

At 0.61x book and ~10–12x EV/EBITDA, the market is pricing a low-return utility with an asset floor, not the owner's targets. The shares now trade near half the parent's purchase price. The balance of evidence supports a "Watch / speculative turnaround" stance. Hard evidence would warrant reassessment: a signed distribution partnership with registrations under way, a sustained return to quarterly operating profit, and a 2026–27 FMD award of historical size. Until then, downside is cushioned by assets but upside is contingent on events not yet visible in the numbers.


Source list (primary aggregators of DART data and press)

  • DART filings as aggregated by ETF Shopping: etfshopping.com/stock/036480, /earnings and /company (retrieved 2026-10-20)

  • Butler: butler.works/ko/companies/00177320, plus peer pages 00415327 (CAVAC), 00145473 (Eagle Vet), 00103547 (Woogene B&G) and 00187415 (Komipharm)

  • ValueLine/DataHero: valueline.co.kr/finance/income, balancesheet and cashflow pages for 036480

  • Sujuradar: sujuradar.com/company/00177320

  • Chickstock: chickstockfi.com/disclosures/20260930900583

  • Dealsite: articles 158132 (2026-03-10), 158976 (2026-03-26), 159102 and 159151 (2026-03-27)

  • eToday: 2026-02-02 (ASF), 2026-02-15 (KVGMP/exports), 2023-05-16 (FMD), 2020-01-02 (PPS contract)

  • Digital Today AI disclosure, 2025-10-15; Nate/Digital Today, 2026-03-13

  • Edaily: 2024-08-21 and 2025-10-15 contract disclosures; 2026-07-08 (CAVAC SAT1 FMD contract)

  • Chuksan News (2026-03); BioTimes (2026-03-10); JoongAng Economy News (2026-03-10); Greened (June 2026)

  • DailyVet: PED-Q Live and VLP Flu Dogivac product notices; KAHPA trade missions; KAHPA market data (2020, 2024, 2025, 2026)

  • Herald Economy (2015 PPS contract); Daehak Journal (2015 Konkuk technology transfer)

  • Financial News (2007 CAVAC market share); Zoetis FY2025 results summary (Feb 2026)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground / educationCompensationSource

Choi Seung-hoon (최승훈)

CEO (대표이사); also CEO of InSilico

Since March 2026

MS and PhD in biophysical chemistry, KAIST. Previously researched molecular modelling and AI-based materials design at Samsung SDI. Worked about two years at a drug-development venture. Founded and leads InSilico, which provides AI and computer-simulation drug-discovery consulting and DX-based quality-management solutions to Samsung Biologics, Hanmi Pharm, Dong-A and others. Holds about 56% of InSilico with related parties.

Not individually disclosed (below the KRW 500M threshold)

Dealsite 2026-03-10, 03-26, 03-27

Lee Jae-hak (이재학)

Senior Managing Director (전무); leads plant operations and manufacturing

—

Led the March 2026 plant tour; responsible for the suspension-culture and bioreactor roadmap and the Eurasian GMP certification

—

Dealsite 2026-03-27

Lee Hoon-gu (이훈구)

Former CEO; former 6.58% shareholder (relative of Lee Dong-kyu)

CEO c. 2023 – March 2026 (approximate)

Sold 250,000 shares to InSilico in 2026

—

DailyVet; Nate/Digital Today (DART)

Cho Hang-won (조항원)

Former CEO

c. 2021–2022 (approximate)

Oversaw the VLP Flu Dogivac and PED-Q Live launches

—

DailyVet

Lee Dong-kyu (이동규)

Former largest shareholder (32.02%)

Until March 2026

Sold 1,216,740 shares to InSilico. Board role not confirmed in sources reviewed.

—

DART via ETF Shopping; Nate

“—” = not publicly disclosed.

Major Shareholders

HolderSharesStake (%)As ofSource

InSilico Co., Ltd.

1,504,64039.60

June 2026

Greened (KIND filing)

Minority shareholders (5,775 holders)

—53.1

2025-12-31

DART via ETF Shopping

Other / unidentified

—

~7.3

Derived

Analyst

Former: Lee Dong-kyu

1,216,74032.02

2025-12-31 (sold March 2026)

DART

Former: Lee Hoon-gu

250,0006.58

2025-12-31 (sold March 2026)

DART

Competitive Landscape

Peer Comparison FY2025

MetricFY2021FY2022FY2023FY2024FY2025

Daesung Microbiological – Revenue (KRW 100M)

240255256238260

Choong Ang Vaccine – Revenue (KRW 100M)

409393419456491

Eagle Vet – Revenue (KRW 100M)

404435428417433

Woogene B&G – Revenue (KRW 100M)

393437579557548

Komipharm – Revenue (KRW 100M)

358398426588525

Metric

FY2021

FY2022

FY2023

FY2024

FY2025

Daesung Microbiological – Operating income (KRW 100M)

3-3-7-167

Choong Ang Vaccine – Operating income (KRW 100M)

4543705865

Eagle Vet – Operating income (KRW 100M)

4236333543

Woogene B&G – Operating income (KRW 100M)

312733

Komipharm – Operating income (KRW 100M)

-53-38-636220

Peer Comparison FY2025 — Revenue FY2025

MetricDaesungChoong Ang VaccineEagle VetWoogene B&G

Revenue FY2025 (KRW 100M)

260491433548

Revenue growth FY2025 (%)

9.27.63.9-1.6

Operating margin FY2025 (%)

2.713.29.90.5

Net margin FY2025 (%)

2.312.69.0-6.6

Market cap (KRW 100M)

219862388186

P/B (x)

0.610.800.710.58

Company Snapshot

138

Employees

1966

Founded

Uiwang, South Korea

Headquarters

SWOT Analysis

Strengths

  • Product breadth and diversification. About 150 products, with the largest single products at only ~5–10% of sales (eToday, citing the periodic report), which limits single-product risk.
  • Modern GMP biologics capacity. A KVGMP vaccine facility completed in 2021 with fully separated live and inactivated lines and automated fill-finish (Dealsite, 2026-03-27).
  • International certification. Eurasian GMP certification for the Uiwang plant (Dealsite), a gateway to Russia, a top-3 export market.
  • Differentiated vaccines. Korea's first VLP animal vaccine (VLP Flu Dogivac) and its first G2b PED live vaccine with dual route; MAFRA "Excellent R&D Innovative Product" designation (DailyVet).
  • Entrenched domestic distribution. About 200 dealers plus PPS and NongHyup channels (eToday; Dealsite), and FMD multiple-supplier awards in 2023, 2024 and 2025.
  • Tangible asset backing. Equity of KRW 35.4bn against a market cap of KRW 21.9bn (P/B 0.61x); land at historic cost of KRW 3.0bn (ValueLine).

Weaknesses

  • Chronic revenue stagnation. FY2025 revenue (KRW 26.0bn) is still 16% below FY2016 (KRW 30.8bn), a 9-year CAGR of -1.9% (DART via ETF Shopping).
  • Thin, volatile margins. Operating margin ranged from -6.5% to +2.7% over FY2022–FY2025, versus CAVAC at 13.2% in FY2025 (Butler).
  • Weak debt service capacity. FY2025 interest coverage of 1.2x; H1 FY2026 operating losses below interest expense (ValueLine).
  • Working-capital drag. A cash conversion cycle of ~246 days; inventories of KRW 10.5bn equal 41% of revenue (analyst-computed).
  • Low export penetration. Exports are ~20–26% of revenue vs peers with far larger international businesses (Dealsite; eToday).
  • Depleted pipeline signal. Capitalised development costs fell from KRW 0.51bn (FY2022) to KRW 0.04bn (Q1 FY2026) (ValueLine).

Opportunities

  • Partner-led export model. A planned global feed-company partnership could lift exports from ~KRW 5bn toward the KRW 20bn+ target (Dealsite, 2026-03-27).
  • Productivity via DX/AX and bioreactors. Suspension culture and bioreactors (~2028) could raise antigen yield and cut cost per dose (Dealsite).
  • Disease-driven demand spikes. ASF reached its 5th national case in Feb 2026 and PED recurred in March 2026, which supports vaccine and disinfectant demand (eToday; DailyVet).
  • Companion-animal growth. The companion-animal share of the Korean market is rising (16.7%), favouring VLP Flu Dogivac (DailyVet).
  • Government export support. MAFRA and KAHPA trade missions (Bangkok, Abu Dhabi, Vietnam, Japan, Brazil; EuroTier in Nov 2026) (DailyVet).
  • Parent IP pipeline. AI drug design and animal-immunology patents brought in through InSilico's new directors (Dealsite, 2026-03-10).

Threats

  • PPS drawdown risk. Only KRW 1.62bn of a KRW 3.975bn FMD ceiling was executed in 2025–26 (DART, 2026-09-30).
  • Competitive intensity. CAVAC (2x revenue) and multinationals compete in the same swine and poultry vaccine categories (Butler).
  • Refinancing risk. KRW 4.6bn of long-term debt became current at FY2025 (ValueLine).
  • Controlling-shareholder conflicts. A possible future merger with an unlisted parent could dilute minorities on unfavourable terms (Dealsite, 2026-03-26; unconfirmed).
  • Regulatory friction. Industry reports slow APQA licensing (KAHPA, Jan 2024) and rising antimicrobial restrictions.
  • Export protectionism. KAHPA cites destination-country self-sufficiency policies as a threat to Korean exports (DailyVet, Jan 2024).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2025-05-14Q1 FY2025 report: revenue KRW 5.2bn (-7.0% YoY), operating loss KRW 0.3bn DART via ETF ShoppingWeak start to the recovery year
2025-05-26Correction filing on a prior single sales/supply contract Sujuradar (DART)Contract execution update
2025-06-23Correction filing on a single sales/supply contract SujuradarSame
2025-06-26Correction filing on a single sales/supply contract SujuradarSame
2025-08-14H1 FY2025 report: Q2 revenue KRW 6.7bn (+19.3%), operating profit KRW 0.7bn DART via ETF ShoppingTurnaround visible
2025-09-30Correction filing reporting final execution of the 2024–25 FMD contract (Oct 2024–Sep 2025; ceiling KRW 3.3bn) SujuradarRealised vs maximum value
2025-10-15New PPS FMD vaccine contract: 2 types, 115,000 vials, KRW 3.975bn ceiling (16.7% of FY2024 revenue), 14 Oct 2025–30 Sep 2026 Digital Today; EdailyLargest recurring domestic order. Shares ~KRW 7,450.
2025-11-10Q3 FY2025 report: revenue KRW 7.2bn (+23.5%), operating profit KRW 0.6bn; 9M revenue KRW 19.1bn (+11%), 9M operating profit ~KRW 1.0bn DART via ETF Shopping; eTodayPeak quarter of the cycle
2025-11-25 to 27Participation in the KAHPA pavilion at VIV MEA 2025, Abu Dhabi (12 firms, ~KRW 40bn of consultations) DailyVetMiddle East market development
2025-12-17Correction filing on a single sales/supply contract SujuradarExecution update
2026-02-02ASF confirmed at a pig farm in Gochang, Jeonbuk (5th national case; ~18,000 pigs culled). Shares jump 25.3% intraday to KRW 8,810. eTodayDisease-event trading pattern
2026-02-04Board declares an FY2025 cash dividend of KRW 75/share (~KRW 0.3bn) DART via ETF ShoppingDividend held flat for a 5th year
2026-02-15Company says 2025 exports recovered via new channels (Cambodia) and credits the KVGMP facility for sales and export gains eTodayStrategy signalling
2026-03-09Share purchase agreement: founding shareholders sell 38.6% to InSilico at KRW 11,000/share (KRW 16.13bn) DART (Nate/Digital Today)Change of control
2026-03-10Deal announced; shares close limit-up +29.92% at KRW 8,120. InSilico announces 3-year targets (revenue KRW 50bn, 10% OPM, 2x share price). JoongAng Economy News; DealsiteRe-rating on the control premium
2026-03-10 to 12Daesung among 8 Korean firms at the KAHPA mission in Bangkok (BITEC); US$11.28M of consultations DailyVetSE Asia pipeline
2026-03-13InSilico files its 5% (large-holding) report; shares +10.1% to KRW 8,480 Nate/Digital TodayDisclosure of deal terms
2026-03-16FY2025 business report filed: revenue KRW 25.99bn (+9.2%), operating profit KRW 0.71bn, net income KRW 0.6bn DART via ETF ShoppingConfirms turnaround
2026-03-17Choi Seung-hoon, now CEO of both companies, outlines partner-led export strategy and reorganisation Dealsite 2026-03-27New management agenda
2026-03-24Press plant tour: details of suspension-culture conversion, bioreactor plan (~2028), DX/AX roadmap and Eurasian GMP Dealsite 2026-03-27Capex and productivity roadmap
c. 2026-03-26Change of largest shareholder to InSilico registered ETF ShoppingClosing
2026-04-24FY2025 dividend paid (KRW 75/share) ETF Shopping—
2026-05-15Q1 FY2026 report: revenue KRW 5.1bn (-2.3%), operating loss KRW 0.5bn DART via ETF ShoppingPost-deal results weaken
2026-06-01 / 02 / 04Parent's open-market purchases reported; stake 39.24% → 39.60% (latest tranche at an average of KRW 6,606) Greened; Butler (disclosure list)Parent buys at a ~40% discount to its acquisition price
2026-06-22Company technical article on PED as an ongoing threat (an outbreak in Chungnam in March 2026) DailyVetMarketing support for the PED franchise
2026-08-14H1 FY2026 report: Q2 revenue KRW 6.0bn (-10.1%), operating loss KRW 0.5bn; H1 revenue KRW 11.1bn (-6.7%) DART via ETF ShoppingSecond consecutive quarterly loss
2026-09-30Correction: final execution of the 2025–26 FMD contract is KRW 1.62bn, 41% of the KRW 3.975bn ceiling and 6.81% of recent revenue Chickstock (DART)Explains part of the FY2026 revenue shortfall
2026-10-20Shares close at KRW 5,750 (-24.0% over 1 year; 41.8% below the 52-week high). No new 2026–27 FMD contract disclosure identified as of this date. ETF ShoppingSentiment at the cycle low

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement (KRW): Revenue to Operating income: Revenue rose from KRW 240 in FY2021 to KRW 260 in FY2025.
Daesung Microbiological Labs. Co., Ltd. — Income Statement (KRW): Revenue to Operating income
Series (KRW)FY2021FY2022FY2023FY2024FY2025
Revenue240255256238260
Cost of sales183207207198196
Gross profit5748484164
SG&A————57.2
Operating income3-3-7-167

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.